奥扎格雷钠对慢性阻塞性肺疾病合并慢性肺源性心脏病的临床治疗研究  

The effect of ozagrel sodium on chronic obstructive pulmonary disease with chronic pulmonary heart disease in clinical trials

作　　者：戴莉莉[1] 陈晓红[1] 张翀[1] 秦斌斌[1] 冯洁[1] 金烨[1] 沈斌[1] 刘炎[1] 

机构地区：[1]上海市第二人民医院,200011

出　　处：《临床内科杂志》2011年第7期450-452,共3页Journal of Clinical Internal Medicine

摘　　要：目的观察奥扎格雷钠注射液对慢性肺源性心脏病患者血小板功能和心肺功能的影响。方法将80例COPD三级合并慢性肺源性心脏病急性发作的患者，随机分为对照组和干预组各40例，对照组给予吸氧、平喘、祛痰、利尿等支持治疗，纠正水电解质失衡，并根据病原学选择有效的抗生素。干预组在上述治疗的基础上给予奥扎格雷钠注射液160mg，1次／天，15天为1疗程。观察两组患者心功能、血小板功能指标、纤溶指标、肺功能、血气分析变化情况。结果干预组治疗后心功能、血小板各项参数改善情况明显好于对照组。FEV1／FVC升高幅度显著大于对照组，血氧分压和血氧饱和度的升高幅度及二氧化碳分压下降幅度显著大于对照组。结论奥扎格雷钠能有效改善肺心病患者血液高凝和低氧状态，降低肺循环阻力。Objective To observe the effects of ozagrel sodium injection on platelet and cardiopulmonary function in patients with CPHD. Method 80 patients with acute exacerbations of level Ⅲ COPD were randomly assigned to control（conventional therapy alone） and intervention group（ convention- al therapy alone ＋ ozagrel sodium injection 160 mg QD） ,course of treatment is 15 days. Scale for heart function,platelet function,fibrinolytic index,pulmonary function,blood gas analysis were measured before and after the treatment. Results After treatment,the turnd hearts function, platelet function in the intervention group was significantly better than the control group,the increase of FEV1/FVC in the intervention group was significantly greater than the control group, blood gas analysis in the intervention group was significant better than the control group. Conclusion Ozagrel sodium could effectively improve blood high condensation and low oxygen state,reduce pulmonary resistance in the patients with CPHD.

关 键 词：慢性肺源性心脏病 慢性阻塞性肺疾病 血栓素A2 奥扎格雷钠 血小板 功能 

分 类 号：R563[医药卫生—呼吸系统] R541.5[医药卫生—内科学]